Teva Pharmaceutical Industries (NYSE:TEVA) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) announced its quarterly earnings data on Wednesday. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01, Zacks reports. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. Teva Pharmaceutical Industries updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $21.57 on Wednesday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business has a 50-day moving average of $19.94 and a 200-day moving average of $18.47. The stock has a market capitalization of $24.43 billion, a price-to-earnings ratio of -25.37, a PEG ratio of 1.11 and a beta of 0.73. Teva Pharmaceutical Industries has a fifty-two week low of $11.48 and a fifty-two week high of $22.80.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TEVA shares. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.63.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.